Family · Pharmaceutical analytical standards
Rivastigmine
A cholinesterase inhibitor, a semi-synthetic derivative of physostigmine, that raises acetylcholine in the brain: in use since 1997 for mild to moderate dementia in Alzheimer's disease and, later, in Parkinson's disease. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.
Did you know?In 2006 it became the first medicine approved for dementia associated with Parkinson's disease, and in 2007, as a transdermal patch, the first dementia treatment applied to the skin.
No product matches your search.
EDQM standards 3
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
